ethyl 5-(4-fluorobenzyl)-3-((2-morpholino-2-oxoethyl)amino)picolinate | 1345733-96-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 5-(4-fluorobenzyl)-3-((2-morpholino-2-oxoethyl)amino)picolinate
• CAS: 1345733-96-1
• 化学式: C₂₁H₂₄FN₃O₄
• 分子量: 401.438
• InChiKey: CFXUKVSPJGRXEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.26
• 重原子数：
  29.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  80.76
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  ethyl 5-(4-fluorobenzyl)-3-((2-morpholino-2-oxoethyl)amino)picolinate 在 sodium ethanolate 作用下， 以 乙醇 、 1,2-二氯乙烷 为溶剂， 生成 N,7-bis[(4-fluorophenyl)methyl]-4-hydroxy-1-(2-morpholino-2-oxo-ethyl)-2-oxo-1,5-naphthyridine-3-carboxamide
  参考文献：
  名称：

  Combining symmetry elements results in potent naphthyridinone (NTD) HIV-1 integrase inhibitors

  摘要：

  A series of naphthyridinone HIV-1 integrase strand-transfer inhibitors have been designed based on a psdeudo-C2 symmetry element present in the two-metal chelation pharmacophore. A combination of two distinct inhibitor binding modes resulted in potent inhibition of the integrase strand-transfer reaction in the low nM range. Effects of aryl and N1 substitutions are disclosed including the impact on protein binding adjusted antiviral activity. (C) 2011 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.08.082
• 作为产物：
  描述：

  ethyl 3-amino-5-[(4-fluorophenyl)methyl]-2-pyridinecarboxylate 在 sodium cyanoborohydride 、 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 ethyl 5-(4-fluorobenzyl)-3-((2-morpholino-2-oxoethyl)amino)picolinate
  参考文献：
  名称：

  Naphthyridinone (NTD) integrase inhibitors 4. Investigating N1 acetamide substituent effects with C3 amide groups

  摘要：

  A series of N1 acetamide substituted naphthyridinone HIV-1 integrase inhibitors have been explored to understand structure-activity relationships (SAR) with various C3 amide groups. Investigations were evaluated using integrase enzyme inhibition, antiviral activity and protein binding effects to optimize the sub-structures. Lipophilicity was also incorporated to understand ligand lipophilic efficiency as a function of the structural modifications. Three representative analogs were further examined in a peripheral blood mononuclear cell (PBMC) antiviral assay as well as in vitro and in vivo drug metabolism and pharmacokinetic studies. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.05.011